greeksoup/ stocks
Stocks / United States / CVS / Q4 FY2024

CVS Health Corp. Q4 FY2024 results: revenue $97.7 billion, up 4.2% on the year

CVS Health Corp. (CVS) reported revenue of $97.7 billion for Q4 FY2024, the quarter ended 31 December 2024, up 4.2% on the same quarter a year earlier. Net income was $1.6 billion, down 19.6% on the year, and diluted earnings per share $1.30. The figures are the company's own, from the 10-K it filed with the SEC on 12 February 2025.

Revenue$97.7 billionup 4.2%
Net income$1.6 billiondown 19.6%
Diluted EPS$1.30
QuarterQ4 FY2024ended 31 December 2024

The quarter, against the one before and a year earlier

LineQ4 FY2024Q3 FY2024Q4 FY2023Change on the year
Revenue97,71095,42893,813+4.2%
Cost of revenue55,26852,94857,419-3.7%
Gross profit42,44242,48036,394+16.6%
Gross margin43.4%44.5%38.8%
Operating income2,3688323,373-29.8%
Operating margin2.4%0.9%3.6%
Interest expense758752690+9.9%
Pre-tax income2,1261052,705-21.4%
Income tax50334.0658-23.6%
Effective tax rate23.7%32.4%24.3%
Net income1,64487.02,046-19.6%
Net margin1.7%0.1%2.2%
Diluted EPS$1.30$0.07$1.59-18.2%

$ million except per share. Fourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ4 FY2024Q3 FY2024Q4 FY2023Change on the year
Operating cash flow1,860-745-2,636n/a
Capital expenditure768670911-15.7%
Free cash flow1,092-1,415-3,547n/a
Free cash flow margin1.1%-1.5%-3.8%
Depreciation and amortisation1,1471,1611,134+1.1%
Share-based compensation137133127+7.9%
Buybacks0.0-1.0-1.0n/a
Dividends paid838837779+7.6%
Dividend per share$0.67$0.67$0.60+9.9%
Diluted shares, weighted1,262m1,259m1,290m-2.2%
Shares outstanding at period end1,260m1,258m1,288m-2.2%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ4 FY2024Q3 FY2024Q4 FY2023Change on the year
Total assets253,215252,427249,728+1.4%
Cash and equivalents8,5866,8758,196+4.8%
Receivables36,46936,17935,227+3.5%
Inventory18,10717,64918,025+0.5%
Goodwill91,27291,27291,272+0.0%
Long-term debt including finance leases60,52759,82458,638+3.2%
Borrowings, as the company tags them63,268n/a60,569+4.5%
Operating lease liabilities14,89915,25816,034-7.1%
Finance lease liabilities1,295n/a1,325-2.3%
Shareholders' equity75,56074,94476,461-1.2%

Quarterly results, the last 12 quarters

Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026
Revenue89,76493,81388,43791,23495,42897,71094,58898,915102,871105,693100,426106,096
Cost of revenue54,68857,41948,07349,99852,94855,26851,05754,00557,04559,06055,44458,862
Gross profit35,07636,39440,36441,23642,48042,44243,53144,91045,82646,63344,98247,234
Gross margin39%39%46%45%45%43%46%45%45%44%45%45%
Operating income3,6903,3732,2713,0458322,3683,3742,381-3,2072,1124,6804,703
Operating margin4%4%3%3%1%2%4%2%-3%2%5%4%
Interest expense693690716732752758785763784787774757
Pre-tax income3,0192,7051,5802,3371052,1262,6171,647-3,4821,3543,9383,977
Tax rate25%24%29%24%32%24%32%38%n/a-116%25%25%
Net income2,2612,0461,1131,77087.01,6441,7791,021-3,9752,9432,9432,979
Net margin3%2%1%2%0%2%2%1%-4%3%3%3%
Diluted EPS$1.75$1.59$0.88$1.41$0.07$1.30$1.41$0.80-$3.13$2.31$2.30$2.31
Operating cash flow2,716-2,6364,9033,089-7451,8604,5561,8977963,3904,2496,345
Capital expenditure545911705638670768743607698784849691
Free cash flow2,171-3,5474,1982,451-1,4151,0923,8131,29098.02,6063,4005,654
Buybacks-3.0-1.03,027-3.0-1.00.00.00.00.00.0n/an/a
Dividends paid779779840858837838840866846845847878
Shares outstanding1,287m1,288m1,252m1,256m1,258m1,260m1,262m1,267m1,270m1,271m1,273m1,278m
Filing10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Source

10-K for the period ended 31 December 2024, filed 12 February 2025, accession 0000064803-25-000007: the filing on EDGAR. All of CVS Health Corp.'s filings: EDGAR company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install